DK0506757T3 - Rekombinant human faktor VIII derivat - Google Patents

Rekombinant human faktor VIII derivat

Info

Publication number
DK0506757T3
DK0506757T3 DK91901327T DK91901327T DK0506757T3 DK 0506757 T3 DK0506757 T3 DK 0506757T3 DK 91901327 T DK91901327 T DK 91901327T DK 91901327 T DK91901327 T DK 91901327T DK 0506757 T3 DK0506757 T3 DK 0506757T3
Authority
DK
Denmark
Prior art keywords
factor viii
human factor
recombinant human
derivative
dna segment
Prior art date
Application number
DK91901327T
Other languages
English (en)
Other versions
DK0506757T4 (da
Inventor
Anneli B Almstedt
Eva Maria Hellstrim
Kerstin Larsson
Peter Lind
Helena Inga Sandberg
Jack Spira
Mona Sydow-Baeckman
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20377785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0506757(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of DK0506757T3 publication Critical patent/DK0506757T3/da
Application granted granted Critical
Publication of DK0506757T4 publication Critical patent/DK0506757T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK91901327T 1989-12-15 1990-12-06 Rekombinant human faktor VIII derivat DK0506757T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8904239A SE465222C5 (sv) 1989-12-15 1989-12-15 Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
PCT/SE1990/000809 WO1991009122A1 (en) 1989-12-15 1990-12-06 A recombinant human factor viii derivative

Publications (2)

Publication Number Publication Date
DK0506757T3 true DK0506757T3 (da) 1999-05-25
DK0506757T4 DK0506757T4 (da) 2006-02-20

Family

ID=20377785

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97103685T DK0786474T3 (da) 1989-12-15 1990-12-06 Rekombinant human faktor VIII derivat
DK91901327T DK0506757T4 (da) 1989-12-15 1990-12-06 Rekombinant human faktor VIII derivat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK97103685T DK0786474T3 (da) 1989-12-15 1990-12-06 Rekombinant human faktor VIII derivat

Country Status (21)

Country Link
EP (3) EP0786474B1 (da)
JP (1) JP2644084B2 (da)
AT (2) ATE232213T1 (da)
AU (1) AU645539B2 (da)
BR (1) BR9007921A (da)
CA (1) CA2071875C (da)
DE (3) DE19975066I2 (da)
DK (2) DK0786474T3 (da)
ES (2) ES2119769T5 (da)
FI (1) FI104260B (da)
HK (2) HK1009290A1 (da)
HU (1) HU211504A9 (da)
IE (1) IE904510A1 (da)
LU (1) LU90457I2 (da)
NL (1) NL990035I2 (da)
NO (1) NO309041B1 (da)
NZ (1) NZ236276A (da)
PT (1) PT96208B (da)
SE (1) SE465222C5 (da)
SG (1) SG66753A1 (da)
WO (1) WO1991009122A1 (da)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
SE468050C (sv) * 1991-03-15 1998-02-11 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
SK282483B6 (sk) * 1992-10-02 2002-02-05 Genetics Institute, Inc. Stabilná kompozícia koagulačného faktora VIII, spôsob jej prípravy a stabilizácie
SE9300509D0 (sv) * 1993-02-16 1993-02-16 Kabi Pharmacia Ab Peg treatment
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
AU6455896A (en) * 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
EP1318198B1 (en) * 1996-05-14 2006-03-22 Biovitrum Ab Process for producing a recombinant polypeptide involving the addition of an inhibitor of chymotrypsins to the cell culture medium
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
CA2312291A1 (en) 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
US6797505B2 (en) 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6586573B1 (en) 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
DK1266006T3 (da) * 2000-03-22 2006-01-16 Octagene Gmbh Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
DK2287288T3 (da) 2002-07-09 2013-01-07 Baxter Int Medium frit for animalsk protein til dyrkning af celler
AU2004215912B2 (en) 2003-02-26 2009-03-26 Nektar Therapeutics Polymer-factor VIII moiety conjugates
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
EP3910063A1 (en) 2003-09-30 2021-11-17 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
MX2007005466A (es) 2004-11-12 2007-10-19 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
AU2006203792B2 (en) 2005-01-10 2011-11-03 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP2359865B1 (en) 2005-04-07 2013-10-02 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
DK2522717T3 (da) 2006-01-04 2014-04-22 Baxter Int Oligopeptid-frie cellekulturmedier
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US20080274958A1 (en) 2006-07-21 2008-11-06 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CN101557830B (zh) 2006-12-15 2016-06-08 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
AU2007347505B2 (en) 2007-02-23 2012-11-22 Sk Bioscience Co., Ltd. Process for producing and purifying factor VIII and its derivatives
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
EP2170919B8 (en) 2007-06-12 2016-01-20 ratiopharm GmbH Improved process for the production of nucleotide sugars
SG10201503304RA (en) 2007-12-27 2015-06-29 Baxter Int Cell culture processes
EP2626080A3 (en) 2008-02-27 2014-03-05 Novo Nordisk A/S Conjugated factor VIII molecules
NZ628987A (en) 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
PL2440239T3 (pl) 2009-06-09 2018-01-31 Prolong Pharmaceuticals Llc Kompozycje hemoglobiny
KR101832937B1 (ko) 2009-07-27 2018-02-28 박스알타 인코퍼레이티드 혈액 응고 단백질 복합체
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2533619C2 (ru) 2009-07-27 2014-11-20 Лайпоксен Текнолоджиз Лимитед Гликополисиалирование белков, не являющихся белками свертывания крови
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
GB0915481D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111
PT2506868T (pt) 2009-12-06 2018-02-23 Bioverativ Therapeutics Inc Polipéptidos quiméricos e hibridos de factor viii-fc, e métodos de utilização dos mesmos
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
MX342858B (es) 2010-03-29 2016-10-13 The Trustees Of The Univ Of Pennsylvania * Sistema de ablacion transgenica inducida farmacologicamente.
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
TW201217526A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Chimeric clotting factors
JP6042335B2 (ja) 2010-09-15 2016-12-14 ノヴォ ノルディスク アー／エス 細胞取込みが低下した第ｖｉｉｉ因子変異体
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
JP6224459B2 (ja) 2011-02-17 2017-11-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組織特異性を改変し、ａａｖ９媒介遺伝子導入を改善するための組成物および方法
PL2717898T3 (pl) 2011-06-10 2019-06-28 Bioverativ Therapeutics Inc. Związki o działaniu prokoagulacyjnym i sposoby ich stosowania
EP3513804B1 (en) 2011-07-08 2022-03-23 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
AU2012324020A1 (en) 2011-12-30 2013-07-18 Grifols, S.A. Method for purifying Factor VIII
EA029560B1 (ru) 2012-01-12 2018-04-30 Байоджен Эмэй Инк. Применение химерного фактора свертывания крови для уменьшения ингибирующего иммунного ответа у субъекта
MX357403B (es) 2012-01-12 2018-07-09 Bioverativ Therapeutics Inc Polipeptidos de factor viii quimericos y usos de los mismos.
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
CN104487452A (zh) 2012-02-15 2015-04-01 阿穆尼克斯运营公司 因子viii组合物及其制备和使用方法
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
US10287564B2 (en) 2012-06-08 2019-05-14 Bioverativ Therapeutics Inc. Procoagulant compounds
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
DK2882450T3 (da) 2012-07-11 2020-02-24 Bioverativ Therapeutics Inc Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf
RU2500818C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАР227, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 2H5 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ ФАКТОРА VIII
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
HUE063051T2 (hu) 2013-02-15 2023-12-28 Bioverativ Therapeutics Inc Optimalizált VIII. faktor gén
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
US9623088B2 (en) 2013-03-15 2017-04-18 Bioverativ Therapeutics Inc. Factor VIII polypeptide formulations
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
CN105848670A (zh) 2013-10-22 2016-08-10 Dbv技术公司 通过诱导对血液因子的耐受治疗血友病的方法
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
ES2813367T3 (es) 2013-12-09 2021-03-23 Sangamo Therapeutics Inc Métodos y composiciones para ingeniería genómica
CN106456718A (zh) 2014-01-10 2017-02-22 比奥根Ma公司 因子viii嵌合蛋白及其用途
KR102567586B1 (ko) 2014-02-04 2023-08-16 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
WO2016012595A1 (en) * 2014-07-25 2016-01-28 Csl Behring Gmbh Improved factor viii preparations suitable for therapeutic use and processes to obtain these
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
ES2763551T3 (es) 2015-04-16 2020-05-29 Univ Emory Promotores y vectores recombinantes para la expresión de proteínas en el hígado y uso de los mismos
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
SG10201913278PA (en) 2016-02-01 2020-02-27 Bioverativ Therapeutics Inc Optimized factor viii genes
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
US20200085915A1 (en) 2016-12-02 2020-03-19 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
US20200263196A1 (en) 2017-09-27 2020-08-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
EP3746136A1 (en) 2018-02-01 2020-12-09 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
KR20210005608A (ko) 2018-04-04 2021-01-14 시질론 테라퓨틱스, 인크. 이식 가능한 입자 및 관련 방법
KR20210020030A (ko) 2018-05-18 2021-02-23 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
AU2019319984A1 (en) 2018-08-09 2021-03-04 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
AU2020298233A1 (en) 2019-06-19 2022-01-20 Bioverativ Therapeutics Inc. Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
KR20230042754A (ko) 2020-08-07 2023-03-29 아미쿠스 세라퓨틱스, 인코포레이티드 소포 표적화 단백질 및 이의 용도
WO2023028456A1 (en) 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Optimized factor viii genes
WO2023056331A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
WO1987004187A1 (en) * 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
JPH0637425B2 (ja) * 1986-11-11 1994-05-18 株式会社クラレ 高沸点（メタ）アクリル酸エステルの製造方法
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JP2586092B2 (ja) * 1988-04-06 1997-02-26 三菱瓦斯化学株式会社 多官能（メタ）アクリル酸エステルの製造法
EP0500734B1 (en) * 1989-11-17 1998-02-11 Novo Nordisk A/S Protein complexes having factor viii:c activity and production thereof

Also Published As

Publication number Publication date
IE904510A1 (en) 1991-07-17
FI922745A0 (fi) 1992-06-12
ATE232213T1 (de) 2003-02-15
DE69032600T3 (de) 2006-07-20
DE69032600T2 (de) 1999-01-07
EP1293513A2 (en) 2003-03-19
HK1009290A1 (en) 1999-05-28
DE19975066I2 (de) 2005-07-07
DE69032600D1 (de) 1998-10-01
SE8904239L (sv) 1991-06-16
SG66753A1 (en) 2001-12-19
CA2071875A1 (en) 1991-06-16
ES2189897T3 (es) 2003-07-16
NO922325D0 (no) 1992-06-12
BR9007921A (pt) 1992-11-10
FI104260B1 (fi) 1999-12-15
SE465222B (sv) 1991-08-12
DE69034040T2 (de) 2003-11-20
FI104260B (fi) 1999-12-15
SE8904239D0 (sv) 1989-12-15
ES2119769T5 (es) 2006-04-16
HK1019449A1 (en) 2000-02-11
EP0506757B1 (en) 1998-08-26
EP0786474B1 (en) 2003-02-05
PT96208B (pt) 1998-05-29
ES2119769T3 (es) 1998-10-16
SE465222C5 (sv) 1998-02-10
DK0786474T3 (da) 2003-03-03
NO922325L (no) 1992-08-11
EP1293513A3 (en) 2003-04-02
HU211504A9 (en) 1995-11-28
JP2644084B2 (ja) 1997-08-25
EP0506757B2 (en) 2005-10-26
JPH05502161A (ja) 1993-04-22
DE69034040D1 (de) 2003-03-13
ATE170219T1 (de) 1998-09-15
AU645539B2 (en) 1994-01-20
NL990035I2 (nl) 2000-01-03
CA2071875C (en) 2006-08-08
DK0506757T4 (da) 2006-02-20
LU90457I2 (fr) 2001-04-13
EP0786474A1 (en) 1997-07-30
WO1991009122A1 (en) 1991-06-27
NL990035I1 (nl) 1999-12-01
EP0506757A1 (en) 1992-10-07
NZ236276A (en) 1993-03-26
PT96208A (pt) 1991-09-30
AU7039391A (en) 1991-07-18
NO309041B1 (no) 2000-12-04

Similar Documents

Publication Publication Date Title
DK0786474T3 (da) Rekombinant human faktor VIII derivat
SE9100799L (sv) Rekombinant derivat av human faktor viii
ATE209215T1 (de) Protegrine
NO971621D0 (no) Keratinocyttvekstfaktoranaloger
DE69840024D1 (de) Antimikrobielle Peptide, abstammend von Ubiquicidin
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
DE69432427D1 (de) Tomate xyloglukan endotransglykosylase
DE68905097T2 (de) Peptid-molekuele, wirksam gegen gram-positive keime.